Skip to content 
Price related data not available
Price related data not available
| Time Frame | CMMB | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | - | -0.48% | 3.24% |
| 1-Month Return | -18.93% | -2.02% | 4.53% |
| 3-Month Return | 5.7% | -5.66% | 3.48% |
| 6-Month Return | -49.7% | 2.33% | 5.58% |
| 1-Year Return | -62.72% | 8.21% | 33.26% |
| 3-Year Return | -74.39% | 9.04% | 69.58% |
| 5-Year Return | -98.79% | 20.66% | 68.93% |
| 10-Year Return | -99.76% | 107.46% | 235.97% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Cost of Revenue | 34.02K | 57.77K | 66.83K | 53.25K | 70.56K | [{"date":"2021-12-31","value":48.22,"profit":true},{"date":"2022-12-31","value":81.88,"profit":true},{"date":"2023-12-31","value":94.72,"profit":true},{"date":"2024-12-31","value":75.47,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | (34.02K) | (57.77K) | (66.83K) | (53.25K) | (70.56K) | [{"date":"2021-12-31","value":-3402300,"profit":false},{"date":"2022-12-31","value":-5777300,"profit":false},{"date":"2023-12-31","value":-6682700,"profit":false},{"date":"2024-12-31","value":-5325100,"profit":false},{"date":"2025-12-31","value":-7055500,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Operating Expenses | 12.37M | 28.53M | 25.46M | 14.74M | 9.57M | [{"date":"2021-12-31","value":43.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.23,"profit":true},{"date":"2024-12-31","value":51.66,"profit":true},{"date":"2025-12-31","value":33.55,"profit":true}] |
| Operating Income | (12.37M) | (28.53M) | (25.46M) | (14.74M) | (9.64M) | [{"date":"2021-12-31","value":-1236700000,"profit":false},{"date":"2022-12-31","value":-2853300000,"profit":false},{"date":"2023-12-31","value":-2545900000,"profit":false},{"date":"2024-12-31","value":-1473900000,"profit":false},{"date":"2025-12-31","value":-964289400,"profit":false}] |
| Total Non-Operating Income/Expense | (222.00K) | 706.00K | 2.48M | 1.59M | 1.15M | [{"date":"2021-12-31","value":-8.97,"profit":false},{"date":"2022-12-31","value":28.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":64.14,"profit":true},{"date":"2025-12-31","value":46.39,"profit":true}] |
| Pre-Tax Income | (12.48M) | (28.18M) | (24.22M) | (13.95M) | (9.07M) | [{"date":"2021-12-31","value":-1247800000,"profit":false},{"date":"2022-12-31","value":-2818000000,"profit":false},{"date":"2023-12-31","value":-2422100000,"profit":false},{"date":"2024-12-31","value":-1394500000,"profit":false},{"date":"2025-12-31","value":-906635700,"profit":false}] |
| Income Taxes | 77.00K | (534.00K) | (1.00) | - | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-693.51,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income After Taxes | (12.55M) | (27.65M) | (24.22M) | - | - | [{"date":"2021-12-31","value":-1255500000,"profit":false},{"date":"2022-12-31","value":-2764600000,"profit":false},{"date":"2023-12-31","value":-2422099900,"profit":false},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (12.48M) | (27.65M) | (24.22M) | (13.95M) | (8.99M) | [{"date":"2021-12-31","value":-1247800000,"profit":false},{"date":"2022-12-31","value":-2764600000,"profit":false},{"date":"2023-12-31","value":-2422100000,"profit":false},{"date":"2024-12-31","value":-1394500000,"profit":false},{"date":"2025-12-31","value":-899500000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (12.48M) | (27.65M) | (24.22M) | (13.95M) | (9.07M) | [{"date":"2021-12-31","value":-1247800000,"profit":false},{"date":"2022-12-31","value":-2764600000,"profit":false},{"date":"2023-12-31","value":-2422100000,"profit":false},{"date":"2024-12-31","value":-1394500000,"profit":false},{"date":"2025-12-31","value":-906635700,"profit":false}] |
| EPS (Diluted) | (1.18) | (1.06) | (1.12) | (0.55) | (0.03) | [{"date":"2021-12-31","value":-118,"profit":false},{"date":"2022-12-31","value":-106,"profit":false},{"date":"2023-12-31","value":-112.14,"profit":false},{"date":"2024-12-31","value":-55.33,"profit":false},{"date":"2025-12-31","value":-3,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| CMMB | |
|---|---|
| Cash Ratio | 7.01 |
| Current Ratio | 9.08 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CMMB | |
|---|---|
| ROA (LTM) | -38.86% |
| ROE (LTM) | -69.54% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CMMB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CMMB | |
|---|---|
| Trailing PE | NM |
| Forward PE | 12.94 |
| P/S (TTM) | 0.00 |
| P/B | 0.98 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | 0.33 |
Chemomab Therapeutics Ltd DRC (CMMB) share price today is $1.67
Yes, Indians can buy shares of Chemomab Therapeutics Ltd DRC (CMMB) on Vested. To buy
Yes, you can purchase fractional shares of Chemomab Therapeutics Ltd DRC (CMMB) via the Vested app. You can start investing in Chemomab Therapeutics Ltd DRC (CMMB) with a minimum investment of $1.
You can invest in shares of Chemomab Therapeutics Ltd DRC (CMMB) via Vested in three simple steps:
The 52-week high price of Chemomab Therapeutics Ltd DRC (CMMB) is $5.88. The 52-week low price of Chemomab Therapeutics Ltd DRC (CMMB) is $1.35.
The price-to-earnings (P/E) ratio of Chemomab Therapeutics Ltd DRC (CMMB) is
The price-to-book (P/B) ratio of Chemomab Therapeutics Ltd DRC (CMMB) is 0.98
The dividend yield of Chemomab Therapeutics Ltd DRC (CMMB) is 0.00%
The market capitalization of Chemomab Therapeutics Ltd DRC (CMMB) is $12.02M
The stock symbol (or ticker) of Chemomab Therapeutics Ltd DRC is CMMB
Consider the share price of Chemomab Therapeutics Ltd DRC as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Chemomab Therapeutics Ltd DRC has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Chemomab Therapeutics Ltd DRC shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Chemomab Therapeutics Ltd DRC stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Chemomab Therapeutics Ltd DRC and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Chemomab Therapeutics Ltd DRC stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
